Neuraxis Begins $33 Million U.S. IPO Effort (NRXS)

A Quick Take On Neuraxis

Neuraxis (NRXS) has filed to raise $33.3 million in an IPO of its common stock, according to an S-1 registration statement.

The firm is commercializing neuromodulation approaches to treating various health conditions in children.

NRXS is still a tiny company and has produced contracting topline revenue year-over-year.

I’ll provide a final opinion when we learn more IPO details from management.

Neuraxis Overview

Carmel, Indiana-based Neuraxis was founded to develop its IB-Stim neuromodulation device for use in treating the following pediatric conditions:

• Functional abdominal pain & irritable bowel syndrome

• Chronic nausea

• Post-concussion syndrome

• Chemotherapy-induced nausea & vomiting

• Cyclic vomiting syndrome

Management is headed by President and CEO Brian Carrico, who has been with the firm since 2012 and was previously employed at Bard Medical and St. Jude Medical.

Below is the status of the firm’s FDA review pipeline:

As of September 30, 2022, Neuraxis has booked fair market value investment of $28.4 million from investors, including Masimo Corporation (MASI) and Brian Hannasch.

Neuraxis – Customer Acquisition

Management has concentrated its marketing focus on 260 children’s hospitals in the U.S., of which 50 hospitals have acquired the firm’s IB-Stim product.

The company is developing its device for the treatment of additional related indications among persons 11 – 18 years of age.

Selling expenses as a percentage of total revenue have fallen as revenues have decreased, as the figures below indicate:

Selling	Expenses vs. Revenue
Period	Percentage
Nine Mos. Ended September 30, 2022	16.6%
2021	16.8%
2020	27.0%

Click to enlarge

(Source – SEC)

The Selling efficiency multiple, defined as how many dollars of additional new revenue are generated by each dollar of Selling spend, fell to negative (0.5x) in the most recent reporting period, as shown in the table below:

Selling	Efficiency Rate
Period	Multiple
Nine Mos. Ended September 30, 2022	-0.5
2021	1.7

Click to enlarge

(Source – SEC)

Neuraxis’ Market & Competition

According to a 2019 market research report by Grand View Research, the global market for inflammatory bowel disease treatments is expected to reach $22 billion by 2026.

This represents a forecast CAGR (Compound Annual Growth Rate) of 4.4% from 2018 to 2026.

Key elements driving this expected growth are continued development of new products owing to a strong pipeline resulting in greater treatment options for patients.

Also, below is a chart showing the historical and forecast growth trajectory for various segments of the U.S. inflammatory bowel disease treatment market in the United States:

Major competitive vendors that provide or are developing related treatments include:

• Takeda Pharmaceuticals (TAK)

• AbbVie (ABBV)

• Janssen Pharmaceuticals

• Pfizer (PFE)

• Bristol-Myers Squibb (BMY)

• Gilead Sciences (GILD)

• Abivax (OTCPK:AAVXF)

• Amgen (AMGN)

• Arena Pharmaceuticals

• Various medical device companies

Neuraxis Financial Performance

The company’s recent financial results can be summarized as follows:

• Dropping topline revenue, year-over-year in the most recent nine-month period

• Lowered gross profit but higher gross margin

• Higher operating losses

• Increased cash used in operations

Below are relevant financial results derived from the firm’s registration statement:

Total Revenue
Period	Total Revenue	% Variance vs. Prior
Nine Mos. Ended September 30, 2022	$ 2,071,653	-8.1%
2021	$ 2,721,286	41.0%
2020	$ 1,930,228
Gross Profit (Loss)
Period	Gross Profit (Loss)	% Variance vs. Prior
Nine Mos. Ended September 30, 2022	$ 1,849,807	-0.3%
2021	$ 2,253,630	55.5%
2020	$ 1,449,139
Gross Margin
Period	Gross Margin
Nine Mos. Ended September 30, 2022	89.29%
2021	82.81%
2020	75.08%
Operating Profit (Loss)
Period	Operating Profit (Loss)	Operating Margin
Nine Mos. Ended September 30, 2022	$ (2,386,012)	-115.2%
2021	$ (2,970,034)	-109.1%
2020	$ (4,120,738)	-213.5%
Net Income (Loss)
Period	Net Income (Loss)	Net Margin
Nine Mos. Ended September 30, 2022	$ (4,766,433)	-230.1%
2021	$ (3,028,032)	-146.2%
2020	$ (3,726,149)	-179.9%
Cash Flow From Operations
Period	Cash Flow From Operations
Nine Mos. Ended September 30, 2022	$ (2,083,689)
2021	$ (2,234,326)
2020	$ (4,139,329)
(Glossary Of Terms)

Click to enlarge

(Source – SEC)

As of September 30, 2022, Neuraxis had $7,820 in cash and $6.9 million in total liabilities.

Free cash flow during the twelve months ended September 30, 2022, was negative ($2.3 million).

Neuraxis IPO Details

Neuraxis intends to raise $33.3 million in gross proceeds from an IPO of its common stock, although the final figure may vary.

No existing shareholders have indicated an interest in purchasing shares at the IPO price.

Management says it will use the net proceeds from the IPO as follows:

(Source – SEC)

Management’s presentation of the company roadshow is not available.

Regarding outstanding legal proceedings, the firm is being sued for various damages in excess of $5 million, is defending itself and believes the charges are without merit.

The sole listed bookrunner of the IPO is Alexander Capital.

Commentary About Neuraxis’ IPO

NRXS is seeking U.S. public capital market funding to continue its R&D efforts and commercialization of its approved treatment indication.

Neuraxis’ financials have produced contracting topline revenue, year-over-year, reduced gross profit year-over-year but higher gross margin, increasing operating losses and rising cash used in operations.

Free cash flow for the twelve months ended September 30, 2022, was negative ($2.3 million).

Selling expenses as a percentage of total revenue have dropped as revenue has decreased; its Selling efficiency multiple was negative (0.5x) in the most recent reporting period.

The firm currently plans to pay no dividends on its common stock and to reinvest any future earnings back into the firm’s R&D and commercialization initiatives.

NRXS’ trailing twelve-month CapEx Ratio was high, which indicates it has spent lightly on capital expenditures despite operating cash use.

The market opportunity for treating IBS and related conditions is large and is expected to grow at a moderate rate of growth through 2026.

Alexander Capital is the sole underwriter and the one IPO led by the firm over the last 12-month period generated a return of negative (22%) since its IPO. This is a lower-tier performance for all major underwriters during the period.

Risks to the company’s outlook as a public company include its tiny size, thin capitalization and contracting year-over-year revenue in the most recent period.

When we learn more about the IPO’s pricing and valuation assumptions, I’ll provide a final opinion.

Expected IPO Pricing Date: To be announced.